Legend Biotech (LEGN) Operating Leases: 2019-2025
Historic Operating Leases for Legend Biotech (LEGN) over the last 3 years, with Sep 2025 value amounting to $88.1 million.
- Legend Biotech's Operating Leases rose 93.01% to $88.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $88.1 million, marking a year-over-year increase of 93.01%. This contributed to the annual value of $44.6 million for FY2024, which is 1.01% up from last year.
- Per Legend Biotech's latest filing, its Operating Leases stood at $88.1 million for Q3 2025, which was up 22.75% from $71.7 million recorded in Q2 2025.
- Over the past 5 years, Legend Biotech's Operating Leases peaked at $88.1 million during Q3 2025, and registered a low of $2.5 million during Q4 2021.
- Its 3-year average for Operating Leases is $51.4 million, with a median of $44.6 million in 2024.
- Per our database at Business Quant, Legend Biotech's Operating Leases decreased by 25.76% in 2021 and then skyrocketed by 842.57% in 2022.
- Legend Biotech's Operating Leases (Quarterly) stood at $2.5 million in 2021, then soared by 842.57% to $23.6 million in 2022, then surged by 87.14% to $44.2 million in 2023, then rose by 1.01% to $44.6 million in 2024, then spiked by 93.01% to $88.1 million in 2025.
- Its Operating Leases stands at $88.1 million for Q3 2025, versus $71.7 million for Q2 2025 and $51.7 million for Q1 2025.